some of the studies under gone for the inhibiton of CETP. Compounds from Ginger, Anthocyanin, Phaleria macrocarpa etc.. but all are in initial stage only detailed studies may come in future.
it is a way of increasing HDL-C by reducing LDL. some statins have good response.
Huge investments have gone into research on developing CETP inhibitors. Most, if not all, CETP inhibitors so far have failed to reduce cardiovascular disease risk. Nutraceuticals may have benefits but might not relate to their inhibition on CETP.
A large number of nutraceuticals claimed to have lipid-lowering activity are currently available both in pharmacies and as over the counter products (OTC) even though, in most cases, their lipid-lowering activity has not been completely assessed and has not been adequately correlated with a concrete reduction in cholesterol level and absence of risk due to their use.For subjects with a history of statin intolerance, drugs like ezetimibe, which has proven efficacy and safety, are an important alternative to statins. Moreover, a PCSK9 antibody molecular biology-based treatment represents a challenging opportunity for statin-intolerant subjects.These pharmacological options for lowering lipids need endpoint studies and these are now been undertaken. While for drugs, it is clear that rigid endpoints studies need to be performed prior to market circulation, for diet/food supplements and nutraceuticals this is not the case. This makes the evidence for the efficacy and safety of the latter weaker, and also emphasizes the need for clinical data substantiating any claim related to cholesterol-lowering efficacy.